| Next 10 |
Ad
OMER Articles Omeros Corporation
home / stock / omer / omer articles
Articles | Omeros Corporation (NASDAQ:OMER)
-
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite falling around 0.1% on Thursday. The Dow traded up 0.01% to 39,912.06...
-
Shares of Fluent Inc (NASDAQ:FLNT) fell sharply during Thursday's session after posting weaker-than-expected quarterly results. Fluent posted ...
-
U.S. stocks traded slightly higher this morning on Thursday. Following the market opening Thursday, the Dow traded up 0.01% to 39,913.23 while the ...
-
U.S. stocks were lower, with the Dow Jones index falling around 80 points on Monday. Shares of Tesla, Inc. (NASDAQ: TSLA) fell during Monday&rsqu...
-
As of Dec. 5, 2023, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in the...
-
The Dow Jones closed higher by over 200 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around th...
-
U.S. stocks traded higher toward the end of trading, with the S&P 500 gaining over 1% on Monday. The Dow traded up 0.93% to 33,983.22 while the...
-
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Monday. The Dow traded up 1.02% to 34,0...
-
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 200 points on Monday. The Dow traded up 0.72% to 33,913.22 while...
Stock Information
Get OMER Alerts
News, Short Squeeze, Breakout and More Instantly...
Ad
-
2024-11-30 06:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
-
Omeros Corporation (Nasdaq: OMER) today announced an update on its progress toward planned resubmission of its biologics license application (“BLA”) for narsoplimab, the company’s first-in-class antibody targeting MASP-2, the effector enzyme of the lectin pathway of complemen...
-
Omeros Corporation (NASDAQ: OMER) is one of today's top gainers. The company's shares have moved 49.88% on the day to $6.28. Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications...